Although c-MYC contributes to tamoxifen resistance, it improves cisplatin sensitivity in ER-positive breast cancer

Tamoxifen (TAM) resistance is a major challenge in the treatment of estrogen receptor-positive (ER(+)) breast cancer. To date, to the best of our knowledge, there are only a few studies available examining the response of patients with TAM-resistant breast cancer to chemotherapy, and the guidelines...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rui, Guo, Shipeng, Yang, Chengcheng, Sun, Lu, Zong, Beige, Li, Kang, Liu, Li, Tu, Gang, Liu, Manran, Liu, Shengchun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050981/
https://www.ncbi.nlm.nih.gov/pubmed/32319562
http://dx.doi.org/10.3892/ijo.2020.4987

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7050981/
https://www.ncbi.nlm.nih.gov/pubmed/32319562
http://dx.doi.org/10.3892/ijo.2020.4987

Ejemplares similares